Viridian Therapeutics, Inc. · NASDAQ:VRDN

T. Rowe Price Associates Inc reported a 5.20% stake in Viridian Therapeutics, Inc. (Schedule 13G)

Event Jun 30, 2026 · Filed Aug 14, 2026

T. Rowe Price Associates Inc reported a 5.20% stake in Viridian Therapeutics, Inc., 5,748,426 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G).

Stake
5.20%
Shares
5,748,426
Intent
Passive
What changed
Crossed above 5%

The filing in full

HolderStakeShares
T. Rowe Price Associates, Inc.5.20%5,748,426

Source

View original at SEC

Related